Racura Oncology (RAC) Investor Presentation summary

Corporate overview and financials

• ASX-listed clinical-stage biopharma focused on cancer care, with a $255.6m market cap and $14.6m cash as of late 2024.

• No debt and 170.4m shares on issue; recent options could raise up to $25m by May 2026.

Market landscape and unmet need

• Anthracyclines are widely used in cancer treatment but cause permanent cardiovascular toxicity, limiting dosing and patient eligibility.

• Global anthracycline use is growing at a 6.6% CAGR, with over 20m doses/year projected by 2030.

• Cancer survivorship is increasing, with 22.5m survivors expected in the US by 2032, raising the importance of managing long-term side effects.

Product innovation and clinical development

• RC220 is a new, more soluble bisantrene formulation for IV delivery, preserving efficacy and offering 20-year IP protection.

• Bisantrene has shown reduced toxicity and strong efficacy in AML and breast cancer, with over 1,500 patients in prior trials.

• Preclinical data show bisantrene protects against doxorubicin-induced heart damage and enhances anti-cancer activity.

• RC220 completed non-clinical safety and toxicology studies in June 2024; Phase 1a/b solid tumour trial to begin H2 2024.